Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FSSV7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $74,174
Award facts
- Contract value 100% obligated
- $74,173.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $74,173.95 by the Defense Logistics Agency on May 30, 2025, for the supply of Entyvio 300 mg vials. The contract carries a firm fixed-price structure with an ultimate completion date of June 23, 2025, and no set-aside designation was applied to this award. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a single-award vehicle valued at $499,999,999 and valid through November 2026, which authorizes the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical products supporting military healthcare facilities worldwide.
The award reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and specialty medications to Department of Defense healthcare sites. Entyvio (vedolizumab) is a biologic medication used to treat inflammatory bowel diseases, demonstrating the contractor's capability to supply specialized pharmaceutical products alongside its broader portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The company's consistent success in competing for DLA pharmaceutical contracts underscores its operational efficiency and reliability in delivering medical supplies to federal healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FSSV7?
SPE2DB25FSSV7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 30, 2025.
How much is contract SPE2DB25FSSV7 worth?
The government has obligated $74,174 on SPE2DB25FSSV7.
Is contract SPE2DB25FSSV7 an order under another contract?
Yes. SPE2DB25FSSV7 is a delivery order under SPE2DB22D9304, an indefinite delivery contract.
Was contract SPE2DB25FSSV7 competed?
The extent of competition for SPE2DB25FSSV7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award